Takeda to Advance FIN-524 Development Program in Ulcerative Colitis
Shots:
- Takeda will lead the development of FIN-524/TAK-524 to treat UC prior to the start of its clinical program & will leverage its expertise in IBD throughout the development process
- Finch plans to provide ongoing technical support through the P-I trial of FIN-524/TAK-524 in the same indication. The companies will continue to advance the program for CD
- In 2017- Takeda & Finch collaborated to develop TAK-524 for IBD under which Finch has received $10M upfront- $4M in milestone- and is eligible to receive an additional ~ $176M as additional milestones along with royalties on WW net sales of the therapy. Finch was primarily responsible for early-stage development activities through P-II study
Ref: Finch Therapeutics | Image: Finch
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com